Andy reflects on his transition from studying biochemistry and economics to a career in investing, highlighting his passion for identifying undervalued companies. He shares the evolution of biotech investments since the completion of the Human Genome Project, emphasizing the challenges of high costs and lengthy processes that initially limited practical applications in the field.
